GSK (GSK) Set to Announce Quarterly Earnings on Wednesday

GSK (NYSE:GSK) is set to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect GSK to post earnings of $0.95 per share for the quarter. GSK has set its FY 2024 guidance at 1.640-1.690 EPS.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The company had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Stock Performance

Shares of NYSE GSK opened at $41.24 on Wednesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. The company has a market cap of $85.47 billion, a P/E ratio of 13.70, a P/E/G ratio of 1.40 and a beta of 0.64. The firm’s fifty day moving average is $41.88 and its two-hundred day moving average is $38.90. GSK has a 52-week low of $33.33 and a 52-week high of $43.84.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were issued a $0.3564 dividend. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s payout ratio is currently 52.82%.

Wall Street Analyst Weigh In

GSK has been the subject of a number of recent research reports. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Morgan Stanley initiated coverage on shares of GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.